Insys Therapeutics has announced that it plans to advance clinical research of a breath activated dronabinol (THC) inhaler in the second half of 2018. The company said that it plans to develop the inhaler for the treatment of anorexia in AIDS and cancer patients and for agitation in Alzheimer's disease patients. In 2015, Insys announced that it had licensed the … [Read more...] about Insys to begin clinical research program for dronabinol inhaler
News
Opiant gets $7.4 million grant for development of intranasal nalmefene
According to Opiant Pharmaceuticals, the National Institutes of Health’s National Institute on Drug Abuse (NIDA) has awarded the company a 3-year grant of about $7.4 million for development of OPNT003 intranasal nalmefene for the treatment of opioid overdose. The company will receive approximately $2.6 million for the first portion of the grant funding period, which … [Read more...] about Opiant gets $7.4 million grant for development of intranasal nalmefene
Highmark and AstraZeneca sign outcomes-based agreement regarding Symbicort
US health insurer Highmark Inc. has announced that it signed an outcomes-based contract with AstraZeneca for Symbicort that provides for a rebate from AstraZeneca if the inhaler does not reduce COPD or asthma symptoms in line with clinical trial results. Highmark's evaluation of Symbicort performance will be based on "specific pharmacy and medical … [Read more...] about Highmark and AstraZeneca sign outcomes-based agreement regarding Symbicort
Penthrox methoxyflurane inhaler approved in Canada and several European countries
Penthrox, a methoxyflurane inhaler, has been approved in Canada for short-term relief of moderate to severe pain resulting from trauma or medical procedures, Medical Developments International (MDI) said. The company announced in June 2017 that its marketing authorization application had been accepted for review by Health Canada. Purdue Pharma, acquired Canadian … [Read more...] about Penthrox methoxyflurane inhaler approved in Canada and several European countries
Pulmotect raises $12 million for development of its PUL-042 inhaled immune stimulant
Pulmotect has closed on a $12 million Series B round to fund continued clinical development of its PUL-042 inhaled immune stimulant, the company said. Pulmotect has now received more than $25 million in funding for development of PUL-042, including awards of $7.1 million from Cancer Prevention & Research Institute of Texas (CPRIT) and $3 million from The National … [Read more...] about Pulmotect raises $12 million for development of its PUL-042 inhaled immune stimulant
Pneuma Respiratory appoints Steven Kesten as President and Chief Medical Officer
Pneuma Respiratory, which introduced a digital soft mist inhaler in November 2017, has announced the appointment of former Boehringer Ingelheim VP of Respiratory Products Steven Kesten as its new President and Chief Medical Officer. Since leaving Boehringer Ingelheim in 2010, Kesten has held VP and Chief Medical Officer positions at Uptake Medical and Cytori … [Read more...] about Pneuma Respiratory appoints Steven Kesten as President and Chief Medical Officer
Trelegy Ellipta approved in Canada
According to GSK and Innoviva, the Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol DPI has been approved in Canada for the treatment of COPD in patients for whom treatment with an ICS/LABA combination is inadequate. Trelegy Ellipta should be available in Canada sometime in June of this year, the companies said. Trelegy Ellipta was approved in the US in … [Read more...] about Trelegy Ellipta approved in Canada
Sunovion launches Lonhala Magnair glycopyrrolate inhalation solution in the US
Sunovion Pharmaceuticals has launched Lonhala Magnair glycopyrrolate inhalation solution for the treatment of COPD in the US, the company said. Lonhala Magnair, also known as SUN-101/eFlow, was approved by the FDA in December 2017. In May 2017, the FDA issued a complete response letter to Sunovion's initial NDA for Lonhala Magnair, which had been accepted for … [Read more...] about Sunovion launches Lonhala Magnair glycopyrrolate inhalation solution in the US
TFF Pharmaceuticals raises $14 million for DPI development
A Texas-based startup called TFF Pharmaceuticals announced that it raised $14 million in a Series A preferred stock offering and that it plans to use the funds for development of dry powder formulations for the treatment of a wide variety of pulmonary diseases. The company said that it has an exclusive license to thin film freezing (TFF) technology developed at … [Read more...] about TFF Pharmaceuticals raises $14 million for DPI development
Promius Pharma submits NDA for intranasal sumatriptan for migraine headaches
Dr. Reddy's subsidiary Promius Pharma has submitted an NDA for its DFN-02 intranasal sumatriptan for the treatment of migraine headaches, the company said. The DFN-02 formulation includes Aegis Therapeutics' Intravail absorption enhancer; Aegis received a US patent for formulations of triptans including Intravail in 2012. In June 2016, Promius announced that a … [Read more...] about Promius Pharma submits NDA for intranasal sumatriptan for migraine headaches